What is metachronous colon cancer?
Metachronous colorectal tumors are defined as primary colorectal tumors developing 6 months after previous colorectal surgery for CRC . Incidence of metachronous CRC varies between 0.5%–9%, with an average of 1.6% . Most metachronous tumours were observed within 24 months after polypectomy or CRC surgery.
What is synchronous and metachronous cancer?
Synchronous cancers were defined as those occurring within 6 months of the first primary cancer, while metachronous cancers were defined as those occurring more than 6 months later (12). Overall survival was defined as the time from first primary cancer diagnosis to death (of any cause).
What are synchronous metastases?
“Synchronous metastasis” and “synchronous second carcinoma”were defined as the diagnosis of a distant metastasis or second carcinoma together with or within a three-month interval of the diagnosis of the primary colon cancer.
What is pt2 colon cancer?
More Information. Stage II colorectal cancer. In stage IIA, cancer has spread through the muscle layer of the colon/rectum wall to the serosa. In stage IIB, cancer has spread through the serosa of the colon/rectum wall to the visceral peritoneum (tissue that lines the organs in the abdomen).
What is synchronous carcinoma?
“Synchronous” tumors refer to cases in which the second primary cancer is diagnosed within 6 months of the primary cancer; “metachronous” tumors refer to cases in which the second primary cancer is diagnosed more than 6 months after the diagnosis of the first primary cancer.
What is a metachronous polyp?
Page 1. Metachronous Neoplasias Arise in a Higher Proportion of. Colon Segments From Which Large Polyps Were Previously. Removed, and Can be Used to Estimate Incomplete Resection. of 10–20 mm Colorectal Polyps.
What is synchronous adenocarcinoma?
Synchronous colorectal carcinoma refers to more than one primary colorectal carcinoma detected in a single patient at initial presentation. A literature review has shown that the prevalence of the disease is approximately 3.5% of all colorectal carcinomas. This disease has a male to female ratio of 1.8:1.